Key Takeaways
- A new AI model can track the pace of brain aging using MRI scans, potentially aiding in cognitive decline and dementia research.
- The model employs a longitudinal approach, comparing baseline and follow-up scans to assess neuroanatomic changes more accurately.
- Findings suggest the model could identify individuals at risk for Alzheimer’s before cognitive symptoms appear, enhancing early intervention strategies.
Innovative Approach to Measure Brain Aging
USC researchers have developed a groundbreaking artificial intelligence model that measures how fast a patient’s brain is aging, providing a significant advancement in the understanding and treatment of cognitive decline and dementia. This non-invasive tool analyzes magnetic resonance imaging (MRI) scans and highlights that faster brain aging correlates with an increased risk of cognitive impairment. Andrei Irimia, the associate professor leading the research, emphasized that this novel approach could transform brain health tracking in both clinical and research settings.
The model differentiates biological brain age from chronological age. Two individuals of the same age may exhibit different biological ages based on their cellular health and functioning. Traditional measures of biological age often rely on blood tests, which are unsuitable for evaluating the brain due to the protective barrier preventing blood cell infiltration. Additionally, the invasive nature of direct brain sampling makes it impractical.
Previously, Irimia and his team highlighted MRI’s potential to estimate brain age using AI by comparing individual brain anatomies to a database of thousands of MRI scans representing various ages and cognitive health statuses. However, this earlier approach had limitations in determining when the brain aging occurred.
The new model utilizes a three-dimensional convolutional neural network (3D-CNN), developed in collaboration with Paul Bogdan, to more accurately assess brain aging over time. Trained on more than 3,000 MRI scans from cognitively normal adults, the model takes a longitudinal approach, analyzing both baseline and follow-up scans from the same individual. Consequently, it can better identify neuroanatomic changes associated with accelerated or decelerated aging. It also generates interpretable “saliency maps” that highlight which specific brain regions are most relevant in estimating aging pace.
Implementations of the 3D-CNN on cognitively healthy adults and Alzheimer’s patients revealed that the AI’s calculations of brain aging speed closely aligned with results from cognitive function tests conducted at different points. This correlation indicates potential for the model as an early biomarker for neurocognitive decline, which could enhance individual treatment approaches based on specific characteristics.
The model’s capabilities also extend to differentiating aging rates across various brain regions, with implications for understanding how genetic, environmental, and lifestyle factors influence brain health. Notably, the study found that the pace of brain aging varied between genders, which could illuminate differences in neurodegenerative disorder risks for men and women.
Looking forward, Irimia noted the model’s potential to identify individuals with accelerated brain aging even before cognitive impairment symptoms emerge. Despite new Alzheimer’s drugs entering the market, their effectiveness may be hampered by late intervention when substantial pathology already exists. The goal is eventually to estimate personalized Alzheimer’s risk levels, providing an early warning system that could lead to preventive measures and tailored treatment strategies.
Ultimately, this AI-based approach signifies an exciting step toward understanding brain health and enhancing the management of cognitive decline, with promising implications for future clinical practice and research.
The content above is a summary. For more details, see the source article.